News UK starts 'largest-ever' trial of possible Parkinson's drugs UK researchers have started a large-scale trial to test a battery of potential Parkinson's drugs to see if they can slow down disease progression.
News Angelini taps Sovargen for epilepsy drug in $550m deal Angelini Pharma has licensed a preclinical-stage mTOR inhibitor from South Korean biotech Sovargen with potential for genetic forms of epilepsy.
News Merck has a $2bn flutter on Skyhawk's RNA platform Merck KGaA has become the latest drugmaker to partner with Skyhawk Therapeutics on its RNA splicing drug discovery engine.
News Roche expands phase 3 plans for Alzheimer's drug Roche has added a phase 3 trial of trontinemab, hoping to show it can delay or prevent progression to Alzheimer's symptoms in preclinical patients.
Market Access BIO Boston: 2025 is shaping up to be a year of challenge – b... What were the major themes to come out of BIO Boston 2025? Despite global events in the background, a fair amount of positivity.
R&D Allogeneic cell therapy isn’t dead, with Brian Culley Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
